II. Indications

  1. Hodgkins Lymphoma
    1. Brentuximab vedotin
  2. Systemic Anaplastic Large Cell Lymphoma
    1. Brentuximab vedotin

III. Mechanism

  1. CD30
    1. CD30 is a Tumor Necrosis Factor (TNF) receptor found on the surface of White Blood Cells
    2. CD30 is overexpressed in hematopoietic malignancies
  2. CD30 Monoclonal Antibody
    1. Conjugate antibodies that deliver cytotoxic drugs to CD30 positive cancer cells

IV. Medications

  1. Brentuximab vedotin (Adcetris)
    1. Conjugated Monoclonal Antibody that delivers the cytotoxic drug monomethyl auristatin E (MMAE) to cancer cells
    2. Used in Hodgkins Lymphoma

V. Dosing

  1. See other references for disease specific dosing protocols

VI. Adverse Effects

  1. Peripheral Neuropathy
  2. Infusion reactions (including Anaphylaxis)
  3. Cytopenia
    1. Neutropenia
    2. Lymphopenia
    3. Thrombocytopenia
  4. Immunosuppression
    1. Risk of opportunistic infections
  5. Hepatotoxicity
  6. Tumor Lysis Syndrome
  7. Pulmonary toxicity
  8. Severe dermatologic conditions
    1. Stevens-Johnson Syndrome
    2. Toxic Epidermal Necrolysis
  9. Other common adverse effects
    1. Hyperglycemia
    2. Gastrointestinal effects (Nausea, Vomiting, Diarrhea, Constipation, Abdominal Pain, weight loss)
    3. Stomatitis and mucositis
    4. Alopecia

VII. Safety

  1. Avoid in Lactation
  2. Avoid in pregnancy (all trimesters, Unknown Pregnancy category)
    1. Use reliable Contraception
  3. Monitoring
    1. Complete Blood Count
    2. Liver Function Tests (including Serum Bilirubin)

VIII. Drug Interactions

  1. Bleomycin
    1. Avoid in combination with Brentuximab (risk of pulmonary toxicity)

Images: Related links to external sites (from Bing)

Related Studies

Ontology: Antigens, CD30 (C0054950)

Definition (NCI) Tumor necrosis factor receptor superfamily member 8 (595 aa, ~ 64 kDa) is encoded by the human TNFRSF8 gene. This protein is involved in ligand-mediated signal transduction, the positive regulation of apoptosis and the inhibition of cell proliferation.
Definition (MSH) A member of the tumor necrosis factor receptor superfamily that may play a role in the regulation of NF-KAPPA B and APOPTOSIS. They are found on activated T-LYMPHOCYTES; B-LYMPHOCYTES; NEUTROPHILS; EOSINOPHILS; MAST CELLS and NK CELLS. Overexpression of CD30 antigen in hematopoietic malignancies make the antigen clinically useful as a biological tumor marker. Signaling of the receptor occurs through its association with TNF RECEPTOR-ASSOCIATED FACTORS.
Concepts Amino Acid, Peptide, or Protein (T116) , Immunologic Factor (T129) , Receptor (T192)
MSH D017730
SnomedCT 4761007
LNC LP14618-0, LP37564-9, MTHU022271, MTHU001643
English Ber-H2 Antigen, CD30 Antigen, Ki-1 Antigen, Antigens, Ki-1, Ber-H2 Antigens, CD30 Antigens, Ki-1 Antigens, Antigen, Ber-H2, Antigen, CD30, Antigen, Ki-1, Antigens, Ber-H2, Antigens, Ki 1, Ber H2 Antigen, Ber H2 Antigens, Ki 1 Antigen, Ki 1 Antigens, CD30 - Cluster of diff ag 30, Cluster of diff antigen 30, BER H02 ANTIGENS, CD 030 ANTIGENS, ANTIGENS KI 01, TUMOR NECROSIS FACTOR RECEPT SUPERFAMILY MEMBER 8, TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY MEMBER 08, KI ANTIGENS 01, TNFRSF8 RECEPT, ANTIGENS CD 030, Antigens, CD30 [Chemical/Ingredient], Ki-1 antigen, CD30 (Ki-1) antigen, CD30 antigen, Antigen CD30, TNF Receptor 8, Lymphocyte Activation Antigen CD30, Tumor Necrosis Factor Receptor Superfamily Member 8, CD30L Receptor, CD30, CD30 Ag, Lymphoid Activation Antigen CD30, TNFRSF8, Cytokine Receptor CD30, Lymphocyte antigen CD30, Ber-H2, CD30 - Cluster of differentiation antigen 30, Cluster of differentiation antigen 30, Ki-1, Lymphocyte antigen CD30 (substance), Receptor, TNFRSF8, TNFRSF8 Receptor, Tumor Necrosis Factor Receptor Superfamily, Member 8, Antigens, CD30
French Récepteur TNFRSF8, Antigène Ber-H2, Antigène Ki-1, Membre-8 de la famille des récepteurs du TNF, Membre-8 de la superfamille des récepteurs du TNF, Membre-8 de la famille des récepteurs au TNF, Membre-8 de la superfamille des récepteurs au facteur de nécrose tumorale, Récepteur TNFRSF-8, Membre-8 de la superfamille des TNF récepteurs, Membre-8 de la superfamille des récepteurs au TNF, Antigène CD30, Antigènes CD30, CD30
Swedish CD30-antigener
Czech antigeny Ki-1, antigeny CD30, antigeny Ber-H2
Finnish CD30-antigeenit
Russian ANTIGENY CD30, ANTIGENY KI-1, CD30 ANTIGENY, KI-1 ANTIGENY, BER-H2 ANTIGENY, BER-H2 АНТИГЕНЫ, CD30 АНТИГЕНЫ, KI-1 АНТИГЕНЫ, АНТИГЕНЫ CD30, АНТИГЕНЫ KI-1
German ANTIGEN CD 030, BER H02 ANTIGENE, CD 030 ANTIGENE, ANTIGEN KI 01, KI ANTIGENE 01, Antigene, CD30-, Antigene, Ki-1-, Ber-H2-Antigene, CD30-Antigene, Ki-1-Antigene
Polish Antygeny CD30
Japanese Ber-H2抗原, CD30抗原, 腫瘍壊死因子受容体スーパーファミリー8, KI-1抗原, Ki-1抗原, Ki1抗原, 抗原-Ber-H2, 抗原-CD30, 抗原-Ki-1, 抗原-Ki1
Spanish antígeno linfocitario CD30 (sustancia), antígeno linfocitario CD30, Antígenos Ber-H2, Antígenos CD30, Antígenos Ki-1, Miembro 8 de la Superfamilia de Receptores de Factores de Necrosis Tumoral
Italian Antigeni CD30
Portuguese Antígenos Ber-H2, Antígenos CD30, Antígenos Ki-1, Membro 8 da Superfamília de Receptores de Fatores de Necrose Tumoral

Ontology: brentuximab vedotin (C2973446)

Definition (NCI) An antibody-drug conjugate (ADC) directed against the tumor necrosis factor (TNF) receptor CD30 with potential antineoplastic activity. Brentuximab vedotin is generated by conjugating the chimeric anti-CD30 monoclonal antibody SGN-30 to the cytotoxic agent monomethyl auristatin E (MMAE) via a valine-citrulline peptide linker. Upon administration and internalization by CD30-positive tumor cells, brentuximab vedotin undergoes enzymatic cleavage, releasing MMAE into the cytosol; MMAE binds to tubulin and inhibits tubulin polymerization, which may result in G2/M phase arrest and tumor cell apoptosis. Transiently activated during lymphocyte activation, CD30 (tumor necrosis factor receptor superfamily, member 8;TNFRSF8) may be constitutively expressed in hematologic malignancies including Hodgkin lymphoma and some T-cell non-Hodgkin lymphomas. The linkage system in brentuximab vedotin is highly stable in plasma, resulting in cytotoxic specificity for CD30-positive cells.
Concepts Immunologic Factor (T129) , Pharmacologic Substance (T121)
MSH C547738
English brentuximab vedotin, Brentuximab Vedotin, BRENTUXIMAB VEDOTIN